{
  "risk_summary_version": "1.0",
  "hazard_rows": [
    {
      "hazard_id": "HZ-001",
      "hazard_name": "Device migration",
      "harm": "Vessel occlusion requiring intervention",
      "severity": 4,
      "probability": 1,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-002",
      "hazard_name": "Coating delamination",
      "harm": "Thrombosis risk",
      "severity": 5,
      "probability": 1,
      "risk_level": "HIGH",
      "residual_risk_level": "MEDIUM",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-003",
      "hazard_name": "Delivery system failure",
      "harm": "Procedure failure requiring repeat intervention",
      "severity": 3,
      "probability": 2,
      "risk_level": "MEDIUM",
      "residual_risk_level": "LOW",
      "last_reviewed": "2023-12-15"
    },
    {
      "hazard_id": "HZ-004",
      "hazard_name": "Biocompatibility reaction",
      "harm": "Local tissue inflammation",
      "severity": 2,
      "probability": 2,
      "risk_level": "LOW",
      "residual_risk_level": "LOW",
      "last_reviewed": "2023-12-15"
    }
  ],
  "overall_benefit_risk_conclusion_prior": "Benefits outweigh risks. Device performance within acceptable limits based on 2022 surveillance data.",
  "overall_benefit_risk_conclusion_current": "Benefits continue to outweigh risks. No new safety signals identified. CAPA-001 closed with confirmed effectiveness. CAPA-002 open â€” monitoring ongoing."
}
